Skip to main content
Home
  • Log in
(0)
  • Discover us
    Discover opnMe®

    Join our vibrant scientific community and delve into our open science portal. Explore exclusive news, research publications, our specialized search tool opnMINER® and FAQs, all dedicated to igniting curiosity and pioneering solutions. Apply for PostDoc research funding on cutting-edge topics. Together, we can drive innovation in areas of high unmet medical need.

    Explore now​
    • About us
    • News
    • Publications
    • opnMINER
    • FAQs
  • Order Molecules
    Order molecules

    Enhance your research by browsing and ordering molecules for free, including free shipping. Use them as experimental biological or chemical tools. Any subsequent IP belongs to you; we encourage you to publish freely.

    Learn more​
    • About ordering molecules
    • View all molecules
    • Selectivity data
  • Collaborate with us
    Collaborate with us

    We are extending a hand to experts around the world, looking for researchers with innovative approaches to address unmet medical needs. From molecules, to funding, to direct cooperation, to molecular biology questions and technology partnerships; we offer a range of collaborative initiatives and resources aimed at transforming lives for generations.

    Discover all​
    • Molecules
    • Biological questions
    • Technological questions
  • PostDoc Grants
    PostDoc grants with opnMe®

    Unlock the next step of your research career with fully funded PostDoc grants at Boehringer Ingelheim. Explore all opportunities for high-caliber talent, pitch your scientific approaches for well-defined research questions, and start your work at one of our discovery research sites.

    Learn more​
    • opn2TALENTS

Don't miss an opportunity to progress your research!  Get first-look access to open calls to submit novel ideas for our research collaboration opportunities and stay informed of new molecule additions.

Subscribe now

  • Log in
  1. Home
  2. Molecules for collaboration
  3. opn2SCREEN: The opnMe molecule library
M4C vial

opn2SCREEN: The opnMe molecule library

How would you leverage the entire opnMe molecule library to address new biological questions in the context of human disease as part of screening and profiling activities?

Download question
Submission template
Submit your answer

For a limited time, opnMe is sharing its entire molecule‑to‑order library with scientists worldwide to support systematic screening and profiling approaches for the validation of novel, disease‑relevant biological hypotheses. The collection comprises 176 high‑quality, well‑characterized molecules, including relevant negative controls.

We invite innovative research proposals aligned with our current discovery research priorities. Submit your proposal by June 17, 2026 (11:59 pm PST) for a chance to access the full opnMe molecule library.

Deadline:
June 17, 2026,
11:59 pm PST
Views: 10
Proposals: 0
0
Share page
Contact page
Download question
Submission template
Submit your answer

More information

Through opnMe1, Boehringer Ingelheim has championed open innovation by making high‑quality, well‑characterized preclinical tool molecules available for free. These molecules have enabled scientists worldwide to test and validate their research hypotheses. While the core objective of opnMe is to allow independent hypothesis-driven research on specific targets, we recognize that accessing the entire opnMe molecule collection may help to address additional objectives.

Access to a well-characterized tool compound library provides a strong foundation for early biological discovery. By enabling controlled perturbation of cellular pathways, the opnMe library enables researchers to run unbiased, scalable screens to generate hypotheses rapidly and uncover disease‑relevant phenotypes. Because each compound’s mode of action and selectivity are well understood, library‑wide responses observed in screening experiments can be interpreted with greater clarity, supporting the identification of novel pathways, signatures, and mechanisms emerging from comparative analyses across the full set.

Hence, we are now making the entire opnMe molecule set available as a single, ready‑to‑screen microtiter plate (MTP) for a short period of time. The library will be shipped in a 384-well MTP, with each tube containing 40 µl of a 10 mM stock solution in DMSO, enabling seamless integration into established screening workflows. In total, the library will comprise 99 active molecules and 77 negative controls, resulting in 176 molecules in total.

We invite scientists to address novel scientific hypotheses with a focus on our current research priorities to address the following question:

How would you leverage the entire opnMe molecule library to address new biological questions in the context of human disease as part of screening and profiling activities?

Please note, we specifically encourage screening and profiling proposals that utilize the entire library rather than single‑target or small‑subset studies.

Please submit your research proposal no later than June 17, 2026, at 11:59 pm PST. All submissions will be evaluated by Boehringer Ingelheim scientists based on novelty, feasibility, and alignment with our current disease priorities (please see below).

The opnMe library contains molecules of the following ten target classes, including:

Target ClassNo. of moleculesNo. of neg controls
Enzyme3024
Epigenetic Target98
GPCR2015
Ion Channel76
Kinase169
Membrane Protein11
Membrane Transporter44
Nuclear receptor11
PPI108
RNA target11

The full list of the molecules included in the opnMe library can be downloaded here.

The following research proposals focusing on the following indications are in scope:

  • Cardiovascular–renal–metabolic diseases: kidney, cardiovascular, liver diseases, and obesity
  • Immunology & respiratory diseases: chronic inflammatory conditions
  • Neuroscience: mental health and neurology
  • Oncology: cancer cell‑directed agents, immuno‑oncology therapies, and combination approaches
  • Eye health: disease progression and earlier‑stage intervention to prevent vision loss

In addition, proposals focusing on:

  • Approaches to evaluate molecular sustainability and environmental impact

And centering on the following approaches and methodologies:

  • Phenotypic screening
  • High‑content or morphological profiling (e.g., cell painting)
  • Chemical genomics & CRISPR‑coupled screening
  • Combination screening
  • Computational approaches where access to the opnMe molecule library would be required for validation of the model

Proposals with ideas for using the molecule library for screening and profiling approaches in the next 12 months.

  • Research proposals without a focus on human disease
  • Any target approaches typically requiring only a single or few molecules:
    • Target validation
    • Assay development
    • Biomarker discovery in targeted experiments
    • Mechanistic deep dives
    • Medicinal chemistry or SAR optimization
  • Proposals with a primary focus on service improvement and/or delivery, such as proposals from contract research organizations and/or suppliers of laboratory reagents
  • Requests with the main purpose of storing compounds without research objectives and definite experimental plan within the next 12 months

If your project is selected, you will obtain access to the opnMe molecule library for your own research. The library covers well-characterized molecules with defined selectivity profiles. A set of negative controls that are included in the library will help you to interpret your scientific experiments and increase confidence in your results. It will be provided to you free of charge, but please note that proforma custom fees may apply to some countries.

Upon receiving the opnMe library, you will be able to pursue your research on your own and publish your results independently. You will also be able to access individual molecules in greater quantity sufficient for follow-up studies upon request.

For this opnMe call, please do not provide any confidential information as part of your proposal. Please indicate that you have additional confidential information to substantiate your proposal. If Boehringer Ingelheim finds the non‐confidential concept proposal sufficiently interesting, they will execute a CDA for confidential discussions.

We are seeking well-structured research proposals outlining a brief non-confidential description of your research objectives, proposed experiments, anticipated timelines, and planned start of the project. Priority will be given to innovative research hypotheses and ideas.

As this offering is specifically designed to support high‑throughput screening, applicants must have direct access to a wet laboratory and have established capabilities for plate‑based screening, hit identification, and hit profiling to effectively evaluate the full molecule collection.

The planned experiments in the context of the proposed submission should start within the next 12 months. In addition, the boundary criteria of the call as outlined in the in-scope and out-of-scope sections must be met.

opnMe.com: a digital initiative for sharing tools with the biomedical research community

Gollner A., Köster M., Nicklin P., Trieselmann T., Klein E., Vlach J., Heine C., Grundl M., Ramharter J., Wyatt D., Chaturvedi M., Ciulli A., Carter K. C., Müller S., Bischoff D., Ettmayer P., Haaksma E., Mack J., McConnell D., Stenkamp D., Weinstabl H., Zentgraf M., Wood C. R., Montel F.

Nat. Rev. Drug Discov. 2022, 21(7):475-476. open access

DOI
PubMed
Sign up to news

Get started with this active call

Submit your application

FAQs

opn2SCREEN

How can I upload a modified version of my proposal after submission?

Show answer
opn2SCREEN

Are the pharmacological profile and structure available for the molecules?

Show answer
opn2SCREEN

Who owns any potential IP arising from novel experimental observations?

Show answer
opn2SCREEN

Will other applicants be able to see my research proposal?

Show answer
opn2SCREEN

Will the opnMe molecule library be shipped free of charge?

Show answer
opn2SCREEN

What is the timeframe for proposal review?

Show answer
opn2SCREEN

Is funding available to support preclinical proof-of-concept studies with these molecules?

Show answer
opn2SCREEN

What if I have additional confidential information?

Show answer
opn2SCREEN

What are the key success criteria on which we base our selection of proposals?

Show answer
opn2SCREEN

How can I request access to the opn2SCREEN molecule library?

Show answer
opn2SCREEN

What are the benefits of a successful proposal for me?

Show answer
See all FAQs
Collaborate with us

Explore other
collaboration opportunities

See all molecules

Collaborate with us on molecules.

Collaborate with us on molecules
Rocket

Partner with us on technology with techMATCH.

Partner with us on technology with techMATCH
Boehringer Ingelheim Logo white
  • https://de.linkedin.com/company/opnme
  • https://www.youtube.com/user/boehringeringelheim/
  • https://www.facebook.com/boehringeringelheim/
  • About us
  • Terms of use
  • Privacy
  • Publications
  • Imprint
  • Contact us

Copyright ©2026 Boehringer Ingelheim International GmbH. All rights reserved.